ICD 10 is coming and these are some new codes. Love the sucked into jet engine one http://t.co/BX4a3PmHZm

Truly honoured to be @AACR2025 & speak on #Precision in #RareCancers “A view from India”. Amazing to share the stage with the great @Dr_R_Kurzrock and @youngkwangchae #DART ! @UmutDisel @SGoswamiMDPhD thank you for being the audience! 🙏 @RFhospital @OncoAlert @oncodaily

@AACR2025 @VivekSubbiah @ANaingMD @geoff_oxnard @DrHaddadRobert @HeadNeckMD @SGoswamiMDPhD @DrChoueiri @Phari But truly overjoyed and overwhelmed by @AdityaSunavs #OralPresentation #Penpulimab #NPC @Dr_R_Kurzrock @VivekSubbiah @BalazsHalmosMD @ANaingMD @Phari @HeadNeckMD @OncoAlert @oncodaily @OncBrothers #BrotherSisterGoals

From Lab to Startup: Dr. Simrit Parmar on Launching Cellenkos https://t.co/Uv1Mu35uhg via @YouTube The world of startups is hard and filled w challenges. The inspiring journey of @spa718 shows tenacity and perseverance that we can all learn from. My last #HealthcareUnfiltered

Thank you ⁦@anantm⁩ and his colleagues from ⁦@EmoryUniversity⁩ for this must read - excellent review for clinicians on Artificial Intelligence https://t.co/PUd0iD60xT ⁦@JCOOP_ASCO⁩ ⁦@OncoAlert⁩ ⁦@EthicsdoctorP⁩

⁦@niravshahmd⁩ presenting CD19.20 CAR-T in DLBCL- a phase 2 registration study with POC manufacturing ⁦@MedicalCollege⁩ #tandem25

Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma | Journal for ImmunoTherapy of Cancer ⁦@MCWCancerCenter⁩ ⁦⁦@Chhabra_mayo⁩ ⁦@Phari⁩

👉#ASH24 wonderful to meet @Phari and Saurabh Chhabra Dr Hari was my first mentor during internal medicine residency at @MedicalCollege 🙏🏽🙏🏽

And of course bumping into our @MedicalCollege crew at ASH-a-Palooza! @Phari and my former co-resident who is now a 2nd year Heme/Onc fellow at @LoyolaOnc #ASH24 #ASHTrainee

https://t.co/Jz6CAmGNGc Excited to share CAR20.19 multicenter data--a nearly 10 year effort. Developed a Phase 1 trial with this construct in 2016, first patient treated at MCW in 2017. Published Phase 1 with target dose, fresh-in/fresh-out CAR cells in Nature Med in 2020.

6/ #ASH24 Abstract 931 (Dhakal) bsAbs and CAR-T are friends, not foes! Talquetamab bridging before BCMA CAR-T. @end_myeloma: "Only place where BCMA must precede GPRC5D is dictionary." In real life, tal's one of the best #MMsm bridging tools we have! https://t.co/L5R1ojx6cb

Checkmate 067 10 year data 🚨 presented by James Larkin with concurrent @NEJM publication. 10 years of ipi+nivo revolutionizing melanoma care and changing the way we treat cancer!! 10y MSS is >50%! #ESMO24 @OncoAlert https://t.co/tHBIwqCppk

Dara-VRd and Dara-KRd quadruplets as initial therapy for high risk myeloma. Griffin trial and Master Trial. @nsc_natalie @SusanBal9 @Myeloma_Doc @szusmani @Phari @ninashah33 @tanyawildes #OpenAccess https://t.co/4YfIREaOV4

Our new paper in @NEJM examines the widespread acquisitions of medical practices by UnitedHealth, Humana, Cigna, and other insurers—what’s driving this trend and what are its implications for patients and clinicians? 1/x

To use a CAR-T metaphor Biden looked like he had ICANS with word finding difficulty and needed dexamethasone. Trump looked like the orderly pretending to be a doctor and ready to take over. There should be talk of an open Democratic convention. That seems like a logical step.

Next generation CAR with novel binding domain! Deep and durable response in high risk patients! Look forward to getting this to our patients! ⁦@MCWCancerCenter⁩ ⁦@EHA_Hematology⁩ #eha2024

Serendipitous encounters have really encapsulated my 1st #ASCO24 experience! Finally met our former @MCWCancerCenter @mcw_oncology division chief @Phari who is an amazing mentor to so many including my mentor @BilalAbidMD and who helped review my first #mmsm pub! What an honor!

MRD negative status (10e-5 to -6) 1 year after AutoHCT and Len maintenance is associated with longer PFS and OS in MM. STaMINA trial #bmtsm #mmsm @mpasca @BMTCTN @BMTjunkie @Phari @JCO_ASCO

This male sumatran orangutan is Raku: he got a wound on his right cheek. Scientists were surprised to spot him applying a medicinal plant on his face: akar kuning (Fibranaurea tinctoria), a type of climbing vine that acts as an analgesic. After about 8 days he applied the chewed

10 suggested action items for physician colleagues suffering under the burden of @ABIMcert MOC. #MedTwitter 1. If your institution allows it, stop participating in MOC. Personally, MOC has no value to me.

4. Urge professional societies in your discipline to End MOC. We should assess societies by their actions not their words. We are dues paying members. Society leadership should listen to their members. Consider quitting societies that are not sincere in efforts to end MOC.